Conference Track

Management of Treatment-Experienced Patients

Source: CCO Official Conference Coverage of the 2008 International AIDS Conference

Capsule Summaries

DUET: Baseline HIV-1 RNA, CD4+ Cell Count, Number of Previous NNRTIs Among Predictors of Response to Etravirine in Treatment-Experienced Patients
Favorable Combined Etravirine, Darunavir Resistance Profile Associated With High Virologic Response Rates in Treatment-Experienced Patients
CD4+ Cell Count Responses in Treatment-Experienced HIV-Infected Patients Treated With Maraviroc-Based Therapy
US-Based Early Access Program Provides Real-World Data on Efficacy, Safety of Etravirine Across Multiple Regimens in Treatment-Experienced Patients
HIV-Infected Patients in Malawi Failing First-Line Therapy Found to Harbor HIV-1 With Extensive Resistance
Switching From Enfuvirtide to Raltegravir Among Heavily Treatment–Experienced Patients Feasible, Well Tolerated in Pilot Study
Significantly Greater Efficacy With Maraviroc vs Placebo in Patients With or Without Triple-Class Resistance
GRACE Study: Safety, Efficacy of Darunavir/Ritonavir in Racially Diverse, Antiretroviral-Experienced Women
Novel NNRTI IDX899 Shown to Reduce HIV-1 RNA Following 7 Days of Monotherapy in Antiretroviral-Naive Patients
Novel NNRTI RDEA806 Demonstrates Antiviral Activity Without Significant Adverse Events in 7-Day Monotherapy Study
Heat-Stable Ritonavir Tablet Demonstrates Bioequivalence With Soft-Gel Capsule Formulation in Single-Dose Pharmacokinetics Study
TRIO Study: 90% of Treatment-Experienced Patients With Multidrug Resistance Achieve Virologic Suppression at Week 24 With Combination of Raltegravir, Etravirine, and Darunavir/Ritonavir

Expert Analysis

Management of Treatment-Experienced Patients

Faculty:

Joseph J. Eron, Jr., MD
Kimberly Y. Smith, MD, MPH
Andrew R. Zolopa, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Recount recent data from the DUET trials describing baseline characteristics predictive of etravirine response
Discuss the results of a study assessing the virologic response in patients treated with the combination of raltegravir, darunavir/ritonavir, and etravirine
Describe the associated affects of maraviroc on CD4+ cell count increases when compared with placebo
Explain the virologic outcomes associated with a switch from enfuvirtide to raltegravir
Identify investigational NNRTIs in early stages of clinical development

CREDIT INFORMATION

Release Date: 10/01/08

Expiration Date: 09/30/09

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Registered Nurses: 1.3 Nursing contact hours

Pharmacists: 1.3 contact hours (0.13 CEUs)

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.